Instructions: Complete The Medication Profile. DOSAGE in Units: I.E. ML/, MG, Etc. ROUTE of Administration: I.E. Po (Oral)

MEDICATIONS
Student Name: Rosa I. Garcia Date: _10/5/10_________________

Instructions: Complete the medication profile. *DOSAGE in units: i.e. ml/, mg, etc. *ROUTE of Administration: i.e. po (oral)
ADVERSE DRUG
REACTIONS:
MEDICATION SAFE PHYSIOLOGIC Common Side
R FREQ &
generic Name: Brand D
DOSAGE O ACTION Effects
O TIME of NURSING IMPLICATIONS
Name: S RANGE U (how medication Life Threatening
T admin S/E Individualized to patient
Classification(s): E* works @ the
E* (am/pm) Drug-Drug
Indications: Max in 24h cellular level Interactions
Food-Drug
Interactions
Inhibits the reabsorption of 1. Assess fluid status during therapy. Monitor
sodium and chloride from the CSE: jaundice, tinnitus, daily weight, I&O ratios, amount and location of
g: furosemide
20 mg 600 mg/day PO Every 12 hrs loop of Henle. Increases hearing impairment, edema, lung sounds, skin turgor, and mucous
renal excretion of water, hypotension, memebranes. Notify physician or other health
B: Lasix
sodium, chloride, magnesium, water/electrolyte care provider if thirst, dry mouth, lethargy,
hydrogen, and calcium. May depletion, pancreatitis, weakness, hypotension, or oliguria occurs.
C: loop diuretics
have renal and peripheral abdominal pain, dizziness,
vasodilatiory effects. anemia 2. Monitor BP and P before and during
I: edema due to CHF, hepatic or
Effectiveness persists in administration.
renal disease. Hypertension.
impaired renal function. LT SE: agranulocytois,
Unlabeled uses Hypercalcemia of
aplastic anemia, cardiac 3. Assess for anorexia, nausea, vomiting, muslce
malignancy
Therapeutic Effects: arrest cramps, paresthesia, and confuison. (digoxin)
Diuresis and subsequent
mobilization of excess fluid. DDI: nitrates,
Decreased blood pressure. antihypertensives, alcohol,
diuretics, piperacillin,
amphotericin B, stimulant
laxitives, corticosteroids,
digoxin, lithium,
aminoglycosides, warfarin,
thrombolytic agents,
anticoagulants
FDI: none
1
Rev F 2010
MEDICATIONS
Student Name: __Rosa I. Garcia__________________ Date: __10/5/10________________

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

R
generic Name: D
DOSAGE O TIME ACTION REACTIONS: NURSING
O Common Side Effects
Brand Name: S RANGE U of (how medication IMPLICATIONS
T Life Threatening S/E
Classification(s): E* admin works @ the Individualized to patient
E* Drug-Drug Interactions
Indications: Max in 24h (am/pm) cellular level Food-Drug Interactions
Interferes with hepatic
g: warfarin synthesis of vitamin K- CSE: cramps, nausea, dermal 1. Maintain PT at 1.5-2.5 and INR at 2-4
5 mg 2-10 mg/day PO Daily dependent clotting factors necrosis, fever depending on diagnonis
B: Coumadin (II, VII, IX, and X)
LT SE: bleeding 2. Determine PT/INR pror to initiaiton of
C: anticoagulants Therapeutic Effects: therapy and then daily until meaintenace
Prevention of DDI: abciximab, androgens, dosage is established.
I: Prophylaxis and thromboembolic events. capecitabine, cefoperazone,
treatment of venous cefotetan, chloral hydrate, 3. Obratin a complete medication history
thrombosis, pulmonary chloramphenicol, prior to start of therapy and whenever
embolism, A-fib with clopidogrel, disulfiram, altered responses to therapy require
embolization. fluconazole, interpretation, extremelyl important
Management of MI, fluoroquinolones, since many drug interfere with the
decreases risk of death, itraconazole, metronidazole, activity of anticoagulant drugs
risk of subsequent MI, plicamycin, thrombolytic
risk of future agents, eptifibatide,
thromboembolic events. tirofiban, ticlopidine,
Prevention of thrombus sulfonamides, quinidine,
formation and emolization NSAIDs, valproates,
after prosthetic valve aspirin, acetaminophen,
placement. alcohol, barbiurates,
hormonal contraceptives
containing extrogen.
FDI: foods high in vitamin K
2
Rev F 2010
MEDICATIONS
Student Name: ___________Rosa I.Garcia_________ Date: ___10/5/10_______________


R
generic Name: D
CSE: fatigue, bradycardia, Monitor apical pulse for 1 full min before
g: digoxin 0.25 mg 15mg/kg PO Daily Increases the force of anorexia, n/v, HA, diarrhea administering. Withhold dose and notify
myocardial contraction. physician if pulse rate is <60 bpm. Also
Prolongs refractory notify health care professional promptly of
B: Lanoxin, Lanoxicaps period of the AV node. LT SE: arrhythmias any significant changes in rate, rhythm, or
Decreases conduction quality of pulse.
C: antiarrhythmics, through the SA and AV DDI: Lasix, Cardizem Monitor intake and output ratios and
inotropics nodes. daily weights. Assess for peripheral edema,
and auscultate lungs for rales/crackles
Therapeutic Effects: FDI: foods with high fiber throughout therapy.
I: Tx of CHF, Increased cardiac output content Geri: Digoxin has been associated with
tachyarrhythmias (positive inotropic effect) an increased risk of falls in the elderly.
and slowing of the heart rate Assess for falls risk and implement
(negative chronotropic prevention strategies per facility protocol
effect). Lab Test Considerations: Evaluate
serum electrolyte levels and renal and
hepatic functions periodically during
therapy. Notify health care professional
before giving dose if patient is hypokalemic.
Hypokalemia, hypomagnesemia, or
hypercalcemia may make the patient more
susceptible to digitalis toxicity
**narrow theraputic range**
**give without regard to meals**
3
Rev F 2010
MEDICATIONS
Student Name: _______Rosa I. Garcia _____________ Date: ____10/5/10______________

MEDICATION
SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG
generic Name: R
D
Brand Name: O Common Side Effects
S RANGE U of (how medication IMPLICATIONS
Classification(s) T Life Threatening S/E
E* admin works @ the Individualized to patient
: E* Drug-Drug Interactions
Max in 24h (am/pm) cellular level Food-Drug Interactions
Indications:
Assess patient routinely for epigastric
g: pantoprazole 40 mg 40 mg/day PO Daily Binds to an enzyme in CSE: HA, abd pain, or abdominal pain and for frank or occult
the presence of acidic diarrhea, fatulence blood in stool, emesis, or gastric aspirate.
B: Protonix gastric pH, preventing the
final transport of LT SE: none Lab Test Considerations: May cause
C: antiulcer agents hydrogen ions into the abnormal liver function tests, including ↑
gastric lumen. DDI: warfarin AST, ALT, alkaline phosphatase, and
I: Erosive esophagitis Therapeutic Effects: bilirubin.
associated with GERD. Diminished accumulation of FDI: none
Decrease relapse rates acid in the gastric lumen,
of daytime and with lessened acid reflux.
nighttime heartburn Healing of duodenal ulcers
symptoms on patients and esophagitis. Decreased
with GERD. acid secretion in
]Pathologic gastric hypersecretory conditions.
hypersecretory
conditions.
4
Rev F 2010
MEDICATIONS
Student Name: ___Rosa I. Garcia_________________ Date: __10/5/10________________


R
generic Name: D
5mg 40 mg/day/ PO Daily ACE inhibitors block CSE: cough, hypotension, Hypertension: Monitor blood pressure
g: lisinopril the conversion of taste disturbances, HA, and pulse frequently during initial dose
angiotensin I to the N/V adjustment and periodically during
B: Prinivil vasoconstrictor therapy. Notify health care professional
angiotensin II. ACE LT SE: agranulocytosis, of significant changes.
C: antihypertensive, ACE inhibitors also prevent the angioedema Assess patient for signs of
inhibitor degradation of bradykinin angioedema (dyspnea, facial swelling). .
and other vasodilatory DDI: NSAIDs, other HTN CHF: Monitor weight and assess
I: management of HTN prostaglandins. ACE meds, antiacids patient routinely for resolution of fluid
and CHF inhibitors also increase overload (peripheral edema,
plasma renin levels and FDI: Food significantly rales/crackles, dyspnea, weight gain,
reduce aldosterone levels. lower absorption jugular venous distention).
Net result is systemic (administer drugs 1 hr Lab Test Considerations: Monitor
vasodilation. before meals). BUN, creatinine, and electrolyte levels
Therapeutic Effects: periodically. Serum potassium, BUN and
Lowering of blood pressure creatinine may be ↑, whereas sodium
in hypertensive patients. levels may be ↓. If ↑ BUN or serum
Improved symptoms in creatinine concentrations occur, dose
patients with CHF reduction or withdrawal may be required.
Monitor CBC periodically during
therapy. Certain drugs may rarely cause
slight ↓ in hemoglobin and hematocrit,
leukopenia, and eosinophilia
5
Rev F 2010
MEDICATIONS
Student Name: ____Rosa I.Garcia ________________ Date: ___10/5/10_______________


R
generic Name: D
2 tsp 160 mg/day PO Every 6 hrs
g: PRN for CSE: dizziness, nausea Assess frequency and nature of cough,
dextromethorphan/guaife cough Suppresses the cough lung sounds, and amount and type of
nesin reflex by a direct effect LT SE: none sputum produced. Unless contraindicated,
on the cough center in the maintain fluid intake of 1500-2000 ml to
B: Robitussin DM medulla. Related to opioids decrease viscosity of bronchial
structurally but has no secretions.
C: allergy, cold, and cough analgesic properties. DDI: MAO inhibitors,
remedies, antitussives antihistamines, alcohol
Therapeutic Effects:
I: Symptomatic relief of Relief of irritating
coughs caused by minor nonproductive cough.
viral upper respiratory FDI: none
tract infections or
inhaled irritants. Most
effective for chronic
nonproductive cough.
A common ingredient in
nonprescription cough and
cold preparations.
6
Rev F 2010
7
Rev F 2010
MEDICATIONS
Student Name: __Rosa I.Garcia______________ Date: 10/5/10

MEDICATION SAFE PHYSIOLOGIC ADVERSE DRUG

R FREQ &
generic Name: D
DOSAGE O ACTION REACTIONS: NURSING
O TIME of Common Side Effects
Brand Name: S RANGE U (how medication IMPLICATIONS
T admin Life Threatening S/E
Classification(s): E* works @ the Individualized to patient
E* (am/pm) Drug-Drug Interactions
Indications: Max in 24h cellular level Food-Drug Interactions
1. Monitor BP and pulse before therapy,
120 mg 360 mg/day Inhibits transport of during dose titration, and periodically
g: diltiazem PO Daily calcium into myocardial and CSE: Av block, during therapy. Monitor ECG periodically
vascular smooth muscle bradycardia, edema, during prolonged therapy. May cause
B: Cardizem
cells, resulting in inhibition dizziness/lightheadedness, prolonged PR interval.
of excitation-contraction headache, pain, dyspnea,
C: antianginals,
coupling and subsequent rhinitis, infection 2. Monitor I&O ratios and daily weight
antiarrythimic (class IV),
contraction.
anthyhpertensives
LT SE: arrhythmias, 3. Routine serum digoxin levels ckeck and
monitored for s/s of digoxin toxicity
abnormal ECG, ventricular
Therapeutic Effects:
I: Hypertension, angina extrasystoles, Stevens-
Systemic vasodilation
pectoris and vasospastic Johnson syndrome, bundle
resulting in decreased
(Prinzemetal’s) angina, branch block
blood pressure. Coronary
Supraventicular
vasodilation resulting in
tachyarrhythmias and rapid
decreased frequency and
ventricual rates in atrial DDI: fentanyl, nitrates,
severity of attacks and
flutter or fibirillation alcohol, quinidine, NSAIDs,
angina. Suppression of
digoxin, bata blockers,
arrhythmias
disopyramide, phenytoin,
phenobarbital,
carbamazepine, cimetidine,
ranitidine, lithium,
theophylline
FDI: grapefruit juice
8
Rev F 2010
FORM B
MEDICATIONS
Student Name: Rosa I. Garcia Date: 10/7/10


R
generic Name: D
20 units 0.7 – 2.5 subcut Every Lower blood glucose by : Assess for symptoms of hypoglycemia
g: insulin units/kg/day aneous morning stimulating glucose uptake CSE: erythema, (anxiety;restlessness; tingling in hands,
in skeletal muscle and fat, lipodystrophy, pruritis, feet, lips, or tongue; chills; cold sweats;
B: Humulin R inhibiting hepatic glucose swelling confusion; cool, pale skin; difficulty in
production. concentration; drowsiness; nightmares or
C: antidiabetics Other actions: LT SE: hypoglycemia, trouble sleeping; excessive hunger;
inhibition of lipolysis and anaphylaxis headache; irritability; nausea;
I: Control of proteolysis, enhanced nervousness; tachycardia; tremor;
hyperglycemia in patients protein synthesis DDI: bata blokers, ACE weakness; unsteady gait) and
with type 1 or type 2 inhibitors hyperglycemia (confusion, drowsiness;
diabetes; can be used to flushed, dry skin; fruit-like breath odor;
treat diabetic FDI: none rapid, deep breathing, polyuria; loss of
ketoacidosis. appetite; nausea; vomiting; unusual thirst)
periodically during therapy.
Monitor body weight periodically.
Changes in weight may necessitate
changes in insulin dose.
Lab Test Considerations: May cause
↓ serum inorganic phosphate, magnesium,
and potassium levels.
Monitor blood glucose every 6 hr
during therapy, more frequently in
ketoacidosis and times of stress. A1C
may also be monitored every 3-6 mo to
determine effectiveness. .
Toxicity and Overdose: Overdose is
manifested by symptoms of
hypoglycemia. Mild hypoglycemia may be
treated by ingestion of oral glucose.
Severe hypoglycemia is a life-threatening
emergency; treatment consists of IV
glucose, glucagon, or epinephrine.
9
Rev F 2010
MEDICATIONS

MEDICATIO ADVERSE DRUG

N PHYSIOLOGI REACTIONS:
SAFE Common Side
generic D
R FREQ & C ACTION
DOSAGE O Effects
Name: Brand O TIME of (how NURSING IMPLICATIONS
RANGE U Life Threatening
Name: S admin medication Individualized to patient
T S/E
E*
Classification E* (am/pm) works @ the Drug-Drug
Max in 24h
Interactions
(s): cellular level
Food-Drug
Indications: Interactions
25 mg 1200 mg/day IM Every 6 hrs. Binds to opiate Assess type, location, and intensity of pain prior to and 1 hr
g: meperdine PRN for pain receptors in the CNS. CSE: confusion, sedation, following IM doses. When titrating opioid doses, increases of 25-50%
Alters the perception hypotension, constipation, should be administered until there is either a 50% reduction in the
B: Demerol of and response to n/v, HA patient's pain rating on a numerical or visual analogue scale or the
painful stimuli, while patient reports satisfactory pain relief. A repeat dose can be safely
C: opioid analgesics producing generalized LT SE: seizures administered at the time of the peak if previous dose is ineffective and
CNS depression. . side effects are minimal..
I: Moderate or DDI: MAO inhibitors, Assess blood pressure, pulse, and respirations before and
severe pain (alone or Therapeutic Effects: alcohol, antihistamines periodically during administration. If respiratory rate is <10/min, assess
with nonopioid Decrease in severity level of sedation. Dose may need to be decreased by 25-50%. Initial
agents). Anesthesia of pain. FDI: none drowsiness will diminish with continued use.
adjunct. Analgesic Assess bowel function routinely. Prevention of constipation should
during labor. be instituted with increased intake of fluids and bulk and with laxatives
Preoperative to minimize constipating effects. Stimulant laxatives should be
sedation administered routinely if opioid use exceeds 2-3 days, unless
contraindicated.
Monitor patients on chronic or high-dose therapy for CNS
stimulation (restlessness, irritability, seizures) due to accumulation of
normeperidine metabolite. Risk of toxicity increases with doses >600
mg/24 hr, chronic administration (>2 days), and renal impairment..
Geri: Meperidine has been reported to cause delirium in the elderly;
older adults are at increased risk for normeperidine toxicity. Monitor
frequently..
Lab Test Considerations: May ↑ plasma amylase and lipase
concentrations. .
10
Rev F 2010
MEDICATIONS


R
generic Name: D
2 mg 8-32 mg/day IM Every 12 hrs
g: ondansetron Blocks the effects of CSE: HA, constipation, Assess patient for nausea, vomiting,
serotonin at 5-HT3- diarrhea, dizziness, abdominal distention, and bowel sounds
B: Zofran receptor sites (selective drowsiness, fatigue, prior to and following administration.
antagonist) located in vagal weakness, abd pain Assess patient for extrapyramidal
C: antimetics, 5-HT3 nerve terminals and the effects (involuntary movements, facial
antagonist chemoreceptor trigger LT SE: none grimacing, rigidity, shuffling walk,
zone in the CNS. trembling of hands) periodically during
I: Prevention of nausea DDI: may be affected by therapy.
and vomiting associated Therapeutic Effects: drugs altering the activity Lab Test Considerations: May cause
with chemotherapy or Decreased incidence and of liver enzymes transient ↑ in serum bilirubin, AST, and
radiation therapy. severity of nausea and ALT levels.
vomiting following FDI: none
chemotherapy or surgery.
11
Rev F 2010
12
Rev F 2010

Instructions: Complete The Medication Profile. DOSAGE in Units: I.E. ML/, MG, Etc. ROUTE of Administration: I.E. Po (Oral)

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Instructions: Complete The Medication Profile. DOSAGE in Units: I.E. ML/, MG, Etc. ROUTE of Administration: I.E. Po (Oral)

Uploaded by

Copyright:

Available Formats

MEDICATIONS

Student Name: Rosa I. Garcia Date: _10/5/10_________________

Student Name: __Rosa I. Garcia__________________ Date: __10/5/10________________

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

FDI: foods high in vitamin K

Student Name: ___________Rosa I.Garcia_________ Date: ___10/5/10_______________

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

**narrow theraputic range**

**give without regard to meals**

Student Name: _______Rosa I. Garcia _____________ Date: ____10/5/10______________

Student Name: ___Rosa I. Garcia_________________ Date: __10/5/10________________

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

Student Name: ____Rosa I.Garcia ________________ Date: ___10/5/10_______________

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

Student Name: __Rosa I.Garcia______________ Date: 10/5/10

MEDICATION SAFE PHYSIOLOGIC ADVERSE DRUG

FDI: grapefruit juice

Student Name: Rosa I. Garcia Date: 10/7/10

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

Student Name: Rosa I. Garcia Date: 10/7/10

MEDICATIO ADVERSE DRUG

Student Name: Rosa I. Garcia Date: 10/7/10

MEDICATION SAFE FREQ & PHYSIOLOGIC ADVERSE DRUG

You might also like

Student Name: Rosa I. Garcia Date: 10/5/10__

Student Name: _____Rosa I.Garcia_ Date: _10/5/10_______________

narrow theraputic range

give without regard to meals

Student Name: _Rosa I. Garcia _ Date: 10/5/10________

Student Name: _Rosa I. Garcia_ Date: 10/5/10____

Student Name: Rosa I.Garcia __________ Date: _10/5/10_______________

Student Name: Rosa I.Garcia____________ Date: 10/5/10